- Home
- TGL vs CANF Comparison
TGL vs CANF Comparison
Compare TGL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- CANF
- Stock Information
- Founded
- TGL 2020
- CANF 1994
- Country
- TGL United States
- CANF Israel
- Employees
- TGL N/A
- CANF N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- CANF Health Care
- Exchange
- TGL Nasdaq
- CANF Nasdaq
- Market Cap
- TGL N/A
- CANF 7.9M
- IPO Year
- TGL 2022
- CANF N/A
- Fundamental
- Price
- TGL $2.17
- CANF $1.09
- Analyst Decision
- TGL
- CANF Strong Buy
- Analyst Count
- TGL 0
- CANF 2
- Target Price
- TGL N/A
- CANF $14.00
- AVG Volume (30 Days)
- TGL 6.6M
- CANF 422.0K
- Earning Date
- TGL 05-13-2025
- CANF 05-13-2025
- Dividend Yield
- TGL N/A
- CANF N/A
- EPS Growth
- TGL N/A
- CANF N/A
- EPS
- TGL N/A
- CANF N/A
- Revenue
- TGL $2,398,398.00
- CANF $674,000.00
- Revenue This Year
- TGL N/A
- CANF $461.72
- Revenue Next Year
- TGL N/A
- CANF N/A
- P/E Ratio
- TGL N/A
- CANF N/A
- Revenue Growth
- TGL N/A
- CANF N/A
- 52 Week Low
- TGL $1.71
- CANF $1.22
- 52 Week High
- TGL $300.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- TGL 35.95
- CANF 34.28
- Support Level
- TGL $2.22
- CANF $1.13
- Resistance Level
- TGL $2.77
- CANF $1.19
- Average True Range (ATR)
- TGL 0.65
- CANF 0.11
- MACD
- TGL 0.15
- CANF -0.02
- Stochastic Oscillator
- TGL 20.52
- CANF 1.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).